X0609 4 2026-09-10 0001534120 Avalo Therapeutics, Inc. AVTX 0001810417 Sullivan Christopher Ryan false C/O AVALO THERAPEUTICS, INC. 1500 LIBERTY RIDGE DRIVE, SUITE 321 WAYNE PA 19087 false true false false Chief Financial Officer 1 Common Stock 2026-09-10 4 M 0 10185 8.04 A 50085 D Common Stock 2026-09-10 4 S 0 10185 17.6197 D 39900 D Stock Option (Right to Buy) 8.04 2026-09-10 4 M 0 10185 0 D 2035-01-28 Common Stock 10185 105815 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. /s/ Christopher Sullivan 2026-09-11